医师

This research has proved that an artificial neural network is capable to differentiate the reactional enhancement of malignant intracranial gliomas in postoperative MR images and the enhancement caused by tumor residual. As a innovative differentiation approach, it requires further studies and researches to determine its applicability in practice, including the increase of training samples, image description standardization, effects to doctoral diagnosis, as well as parameter optimization. With improvements in these elements, the performance of the network will be optimized.

本研究成功地证明了人工神经网络能够鉴别颅内恶性胶质瘤术后磁共振图像的反应性强化与肿瘤残存所致的强化，为解决二者的鉴别这一复杂问题提供了一个新的方法，但是本研究只是初步的应用探讨，能否在实际中应用，还有待于进一步的研究，如训练样本的增加、图像描述的规范化、对医师诊断影响程度、参数的优化等，网络的性能会不断完善和提高。

This research has proved that an artificial neural network is capable to differentiate the reactional enhancement of malignant intracranial gliomas in postoperative MR images and the enhancement caused by tumor residual. As a innovative differentiation approach, it requires further studies and researches to determine its applicability in practice, including the increase of training samples, image de脚本ion standardization, effects to doctoral diagnosis, as well as parameter optimization. With improvements in these elements, the performance of the network will be optimized.

本研究成功地证明了人工神经网络能够鉴别颅内恶性胶质瘤术后磁共振图像的反应性强化与肿瘤残存所致的强化，为解决二者的鉴别这一复杂问题提供了一个新的方法，但是本研究只是初步的应用探讨，能否在实际中应用，还有待于进一步的研究，如训练样本的增加、图像描述的规范化、对医师诊断影响程度、参数的优化等，网络的性能会不断完善和提高。

Previously, Dr. Mahon and colleagues conducted a pilot study and explored the feasibility of discontinuing imatinib in CML patients who had experienced a complete molecular response. Of the 15 patients included in the cohort, 7 relapsed within 6 months, but they were able to reattain a complete molecular response after imatinib was restarted. The other 8 patients remain in remission after the discontinuation of imatinib (median follow-up is 37 months).

之前，Mahon医师等人主导一个先驱研究，探索完整分子生物学上缓解之CML病患停用imatinib的可能性，在总共15名病患中，7人在6个月内復发，但他们可以在再度使用imatinib之后再度达到完整分子生物学上缓解，其他8个病患在停用imatinib之后持续缓解(平均追踪期为37个月)。

Previously, Dr. Mahon and colleagues conducted a pilot study and explored the feasibility of discontinuing imatinib in CML patients who had experienced a complete molecular response. Of the 15 patients included in the cohort, 7 relapsed within 6 months, but they were able to reattain a complete molecular response after imatinib was restarted. The other 8 patients remain in remission after the discontinuation of imatinib (median follow-up is 37 months).

之前，Mahon医师等人主导一个先驱研究，探索完整分子生物学上缓解之CML病患停用imatinib的可能性，在总共15名病患中，7人在6个月内复发，但他们可以在再度使用imatinib之后再度达到完整分子生物学上缓解，其他8个病患在停用imatinib之后持续缓解(平均追踪期为37个月)。

Previously, Dr. Mahon and colleagues conducted a pilot study and explored the feasibility of discontinuing imatinib in CML patients who had experienced a complete molecular response. Of the 15 patients included in the cohort, 7 relapsed within 6 months, but they were able to reattain a complete molecular response after imatinib was restarted. The other 8 patients remain in remission after the discontinuation of imatinib (median follow-up is 37 months).

之前，Mahon医师等人主导一个先驱研究，探索完整分子生物学上缓解之CML病患停用imatinib的可能性，在总共15名病患中，7人在6个月内复发，但他们可以在再度使用imatinib之后再度达到完整分子生物学上缓解，其它8个病患在停用imatinib之后持续缓解(平均追踪期为37个月)。

"We hope that this study will reawaken an awareness in clinicians that this is a proven therapy that is being significantly underutilized in our highest-risk patients."

我们希望此项研究可以再度呼起临床医师的关注：他丁类药物疗效确凿对于最高危人群的应用明显不足。

They have some other patients who have electrodes implanted in the same location and may approach them about participating in a further study of this effect, he said. The institutional review board approval for the first patient was to look at side effects and complications of auditory cortex stimulation, so this study was technically covered by that approval, Dr. De Ridder noted. To study this effect in other patients will require a new application.

他表示，仍有许多植入电极于同样位置的病患，可能可以邀请他们加入往后的研究；De Ridder医师表示，机构的伦理委员会核准第一位病患的原因在于要检验植入电极的副作用、以及听觉皮质刺激的并发症，因此这项研究是技术上由该核准案涵盖的；若要在其它病患身上研究此种效应，则需要新的核准案。

They have some other patients who have electrodes implanted in the same location and may approach them about participating in a further study of this effect, he said. The institutional review board approval for the first patient was to look at side effects and complications of auditory cortex stimulation, so this study was technically covered by that approval, Dr. De Ridder noted. To study this effect in other patients will require a new application.

他表示，仍有许多植入电极於同样位置的病患，可能可以邀请他们加入往后的研究；De Ridder医师表示，机构的伦理委员会核准第一位病患的原因在於要检验植入电极的副作用、以及听觉皮质刺激的并发症，因此这项研究是技术上由该核准案涵盖的；若要在其他病患身上研究此种效应，则需要新的核准案。

These findings have no implications for the out-of-body experience as it relates to near-death experiences, Dr. De Ridder said. Spontaneous out-of-body experiences have also been previously reported in epileptic patients, those with migraine, and, in a recent report, have been induced in healthy volunteers using a virtual-reality system, although not in this kind of reliable way.

De Ridder医师表示，这些发现并不如濒死经验那样的有关联，自发性的灵魂出窍体验过去也曾于癫痫病患、偏头痛病患身上发现，且在最近的一项报告中，也曾在一位使用虚拟实境系统的健康自愿者身上看到，虽然并不是以像这样可靠的方法证实。

These findings have no implications for the out-of-body experience as it relates to near-death experiences, Dr. De Ridder said. Spontaneous out-of-body experiences have also been previously reported in epileptic patients, those with migraine, and, in a recent report, have been induced in healthy volunteers using a virtual-reality system, although not in this kind of reliable way.

De Ridder医师表示，这些发现并不如濒死经验那样的有关联，自发性的灵魂出窍体验过去也曾於癫痫病患、偏头痛病患身上发现，且在最近的一项报告中，也曾在一位使用虚拟实境系统的健康自愿者身上看到，虽然并不是以像这样可靠的方法证实。

I didn't watch TV last night, because it .

昨晚我没有看电视，因为电视机坏了。

Since this year, in a lot of villages of Beijing, TV of elevator liquid crystal was removed.

今年以来，在北京的很多小区里，电梯液晶电视被撤了下来。